INMB INmune Bio, Inc.: Multiplikator Forward P/S

INmune Bio, Inc. (INMB) specializes in developing immunotherapies to combat Alzheimer's disease. The forward P/S multiple confirms market expectations, where the 767.40 level captures the current valuation. A high reliance on external research centers is offset by strict internal oversight. Furthermore, drug development is not subject to economic cycles, demonstrating high resilience to macroeconomic fluctuations.

The forward P/S reflects the ratio of current market capitalization to projected revenue, allowing investors to track the dynamics of market sales expectations and separate the fundamental trend from volatility. By analyzing this forward price-to-sales chart, one can assess the risk of overpaying for the innovations of INmune Bio, Inc. (INMB) in the field of Alzheimer's disease therapy, where the asset's high valuation is justified by the potential of breakthrough immunological developments.